Short-course radiation followed by mFOLFOX-6 plus avelumab for locally-advanced rectal adenocarcinoma
Authors:
- Ali ShamseddineAli Shamseddine
- Youssef H. ZeidanYZYoussef H. Zeidan
- Malek KreidiehMKMalek Kreidieh
- Ibrahim KhalifehIKIbrahim Khalifeh
- Rim TurfaRTRim Turfa
- Joseph KattanJKJoseph Kattan
- Deborah MukherjiDMDeborah Mukherji
- Sally TemrazSally Temraz
- Kholoud AlqasemKAKholoud Alqasem
- Rula AmarinRARula Amarin
- Tala Al AwabdehTATala Al Awabdeh
- Samer DeebaSDSamer Deeba
Open Access
- 1 September 2020
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 20 (1) , 1-11
Abstract
Background: Current standard practice for locally advanced rectal cancer (LARC) entails a multidisciplinary approach that includes preoperative chemoradiotherapy, followed by total mesorectal excision, and then adjuvant chemotherapy. The latter has been accompanied by low compliance rates and no survival benefit in phase III randomized trials, so the strategy of administering neoadjuvant, rather than adjuvant, chemotherapy has been adapted by many trials, with improvement in pathologic complete response. Induction chemotherapy with oxaliplatin has been shown to have increased efficacy in rectal cancer, while short-course radiation therapy with consolidation chemotherapy increased short-term overall survival rate and decreased toxicity levels, making it cheaper and more convenient than long-course radiation therapy. This led to recognition of total neoadjuvant therapy as a valid treatment approach in many guidelines despite limited available survival data. With the upregulation (PDL-1) expression in rectal tumors after radiotherapy and the increased use of in malignant melanoma, the novel approach of combining immunotherapy with chemotherapy after radiation may have a role in further increasing pCR and improving overall outcomes in rectal cancer. Methods: The study is an open label single arm multi- center phase II trial. Forty-four recruited LARC patients will receive 5Gy x 5fractions of SCRT, followed by 6 cycles of mFOLFOX-6 plus avelumab, before TME is performed. The hypothesis is that the addition of avelumab to mFOLFOX-6, administered following SCRT, will improve pCR and overall outcomes. The primary outcome measure is the proportion of patients who achieve a pCR, defined as no viable tumor cells on the excised specimen. Secondary objectives are to evaluate 3-year progression-free survival, tumor response to treatment (tumor regression grades 0 & 1), density of tumor-infiltrating lymphocytes, correlation of baseline Immunoscore with pCR rates and changes in PD-L1 expression. Discussion: Recent studies show an increase in PD-L1 expression and density of CD8+ TILs after CRT in rectal cancer patients, implying a potential role for combinatory strategies using PD-L1- and programmed-death- 1 inhibiting drugs. We aim through this study to evaluate pCR following SCRT, followed by mFOLFOX-6 with avelumab, and then TME procedure in patients with LARC. Trial registration: Trial Registration Number and Date of Registration: ClinicalTrials.gov NCT03503630, April 20, 2018.Keywords
Funding Information
- Merck KGaA (Unknown)
This publication has 67 references indexed in Scilit:
- Short-course radiotherapy followed by neo-adjuvant chemotherapy in locally advanced rectal cancer – the RAPIDO trialBMC Cancer, 2013
- Tumor Regression Grading of Gastrointestinal Carcinomas after Neoadjuvant TreatmentFrontiers in Oncology, 2013
- Immunologic Correlates of the Abscopal Effect in a Patient with MelanomaNew England Journal of Medicine, 2012
- Radiation-induced effects and the immune system in cancerFrontiers in Oncology, 2012
- Radiation as an immunological adjuvant: current evidence on dose and fractionationFrontiers in Oncology, 2012
- Timing of Surgery Following Preoperative Therapy in Rectal Cancer: The Need for a Prospective Randomized Trial?Diseases of the Colon & Rectum, 2011
- T-Cell Responses to Survivin in Cancer Patients Undergoing Radiation TherapyClinical Cancer Research, 2008
- Radiotherapy augments the immune response to prostate cancer in a time‐dependent mannerThe Prostate, 2008
- The total mesorectal excision specimen for rectal cancer: a review of its pathological assessmentJournal of Clinical Pathology, 2006
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989